RENALdo Program - Early Assessment of CKD

Seeking an accredited education program where you can apply what you learn using EMR? Look no further!
Sick of cumbersome chart audits? Read on! “Where’s RENALdo?” is a new, accredited assessment activity that gives you a chart audit at the click of a button, letting you focus your time on optimizing chronic kidney disease (CKD) management.

Please note that this program is available in English only and certified as a National Mainpro+ program offered outside Quebec.

The Program

Earn up to 18 certified Mainpro+® credits by completing this assessment program in 4 simple steps:

  • PART 1 LISTEN TO A CASE
    "Find What's Missing for Renaldo", includes pre-test and post-test questions hosted on the CPD Network site
    (1 hour)
  • PART 2 INSTANTLY IDENTIFY 10 PATIENTS AND REVIEW THEIR CHARTS
    Using the Khure Health platform, instantly find 10 "Renaldo-like" patients with CKD at risk of progression. Consider measures to reduce their risk. Document your quality improvement plan in a template and consider sending your questions to the faculty through a Q&A feature on the platform. Click here for an overview of the Khure Cloud-Secure Platform.
    (4 hours)
  • PART 3 REFLECTION ON PRACTICE CHANGES
    Eight weeks after your chart audit and QI plan, complete a questionnaire
    (1 hour)
  • Claim your credits!
    We invite you to complete an evaluation and obtain your participation certificate

Please note that this program is available in English only and certified as a National Mainpro+ program offered outside Quebec.

Please register or login in order to access this content

Program Faculty

Planning Committee MemberDisclosures
ALAN BELL MD, CCFP, FCFP
Assistant Professor,
Department of Family and Community Medicine,
University of Toronto
Toronto, ON
Dr. Bell received research funding, honoraria, as well as served on advisory boards and as a speaker for CPD Network Association, Amgen, Bristol Myers Squibb, Janssen, AstraZeneca, Novartis, Pfizer, Bayer, Eli Lilly, Boehringer Ingelheim, HLS Therapeutics, Spectrum Therapeutics, Sanofi, Bausch Health, and Akcea.
JEFFREY HABERT MD, CCFP, FCFP
Assistant Professor,
Department of Family and Community Medicine,
University of Toronto
Toronto, ON
Dr. Habert received honoraria and had consulting roles, as well as served on advisory boards and as a speaker for CPD Network Association, Allergan, Alliance, Academy, Amgen, Antibody, AstraZeneca, BMS, Bayer, Boehringer Ingelheim, Brandaide, Bridge, CHRC, CTA, CCRN, Eisai, Eli Lilly, Four Health Comm, Janssen, Lundbeck, Master Clinician, Meducom, MedPlan, MDBriefcase, Novartis, Novo Nordisk, Otsuka, Pfizer, Purdue, Servier, and STA.
JAMES KIM MBBCH, PGDIP
Assistant Professor,
Department of Family Medicine,
University of Calgary
Calgary, AB
Dr. Kim received research funding, honoraria, as well as served on advisory boards and as a speaker, and had consulting roles for CPD Network Association, Abbott, Abbvie, AstraZeneca, BD, Boerhinger Ingelheim, Eli Lilly, GSK, Janssen, Novo Nordisk, Miravo Pharm, Moderna, Pfizer, Takeda, Sanofi, Teva, GSK, MDBriefcase, HIT Global, Academy for Continued Advancement in Healthcare Education, Family Physician Airway Group of Canada, and PPME.
LOUISE MOIST MD, MSC, FRCPC, CCPE
Professor of Medicine and Epidemiology Deputy Chair
Division of Nephrology
Schulich School of Medicine and Dentistry
Western University
London, ON
Dr. Moist received research funding, honoraria, as well as served on advisory boards, consult meetings and as a speaker, for CPD Network Association, Janssen, AstraZeneca, Otsuka, Ortho, Boerhinger Ingelheim, Knight Pharmaceuticals, Bayer, and EMPA Kidney site.
JORDAN WEINSTEIN MD, FRCPC
CPD Network Representative (Physician Organization)
Associate Professor of Medicine
University of Toronto Nephrologist
St. Michael’s Hospital Director, UKidney.com
Toronto, ON
Dr. Weinstein received research funding, honoraria, as well as served on advisory boards and as a speaker, for CPD Network Association, BI-Lilly, Alexion, Merck, Amgen, Janssen, Otsuka, AstraZeneca, and Bayer.
This program has received an educational grant or in-kind support from AstraZeneca Canada.

cpdisup